Abstract:Although hormonal therapy (HT) inhibits the growth of hormone receptor-positive (HR+) breast and prostate cancers, HT resistance frequently develops within the complex metastatic microenvironment of the host organ (often the bone), a setting poorly recapitulated in 2D culture systems. To address this limitation, we cultured HR' breast cancer and prostate cancer spheroids and patient-derived organoids in 3D extracellular matrices (ECM) alone or together with bone marrow stromal cells (BMSC). In 3D monocultures, antiestrogens and antiandrogens induced anoikis by abrogating anchorage-independent growth of HR+ cancer cells but exhibited only modest effects against tumor cells residing in the ECM niche. In contrast, BMSC induced hormone-independent growth of breast cancer and prostate cancer spheroids and restored lumen filling in the presence of HR-targeting agents. Molecular and functional characterization of BMSC-induced hormone independence and HT resistance in anchorage-independent cells revealed distinct context-dependent mechanisms. Cocul tures of ZR75-1 and LNCaP with BMSCs exhibited paracrine IL6-induced HT resistance via attenuation of HR protein expression, which was reversed by inhibition of IL6 or JAK signaling. Paracrine IL6/JAK/STAT3-mediated HT resistance was confirmed in patient-derived organoids cocultured with BMSCs. Distinctly, MCF7 and T47D spheroids retained ER protein expression in cocultures but acquired redundant compensatory signals enabling anchorage independence via ERK and PI3K bypass cascades activated in a non-IL6-dependent manner. Collectively, these data characterize the pleiotropic hormone-independent mechanisms underlying acquisition and restoration of anchorage-independent growth in H ft' tumors. Combined analysis of tumor and microenvironmental biomarkers in metastatic biopsies of HT-resistant patients can help refine treatment approaches. Significance: This study uncovers a previously underappreciated dependency of tumor cells on HR signaling for anchorage-independent growth and highlights how the metastatic microenvironment restores this malignant property of cancer cells during hormone therapy.

The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer

Endocrine Resistance in Breast Cancer: Current Status and a Perspective on the Roles of Mirnas (Review)

Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment

Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies.

Mechanisms of endocrine therapy resistance in breast cancer

Endocrine Therapy Resistance: Current Status, Possible Mechanisms and Overcoming Strategies

Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy

Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment

Advances in Targeted Therapy for Overcoming Endocrine Therapy Resistance in Breast Cancer

Mechanisms of endocrine resistance in hormone receptor-positive breast cancer

The complex interplay of tumor-infiltrating cells in driving therapeutic resistance pathways

The tumor microenvironment: a key player in multidrug resistance in cancer

The Role of the Tumor Microenvironment in Triple-Positive Breast Cancer Progression and Therapeutic Resistance

The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment

Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance

Decoding tumor microenvironment: EMT modulation in breast cancer metastasis and therapeutic resistance, and implications of novel immune checkpoint blockers

Tumor microenvironment promotes breast cancer chemoresistance

Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches

Treatment for the Endocrine Resistant Breast Cancer: Current Options and Future Perspectives

Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies